Abstract
The treatment of HTA plays a central part in the management of Chronic Kidney Disease (CKD) in all its stages, especially in patients following a substitute treatment of renal functions. HBP can be both the cause and the consequence of CKD. The HBP control in CKD patients represents one of the most important concerns of clinicians. HBP treatment is non pharmacological as well as pharmacological.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
